
16/08/2025
**A Golden Opportunity for Pakistan in the Bio similar Market**
By : Professor Dr. Yasir Mahmood
The global bio similar market is rapidly shifting from U.S. dominance to Asia, currently valued at around $40 billion annually and growing fast. South Korea’s Celltrion and Samsung Bioepis hold over 53% market share in top products, while China and Malaysia are also emerging as strong players. Europe remains the largest market, but the fastest growth is happening in the Asia-Pacific region. Most new bio similar in the U.S. come from non-American companies, and America’s market share is dropping quickly. If Pakistan captures even 5% of this market, it could earn about $2 billion annually—almost 8 times its current pharma exports. To achieve this, DRAP must be upgraded to global standards, biotech parks established, skilled workforce developed, and partnerships made with Korea, China, and Malaysia focusing on specific bio similar sectors so Pakistan can become a competitive export hub.
Professor Dr. Yasir Mahmood
: